NCT03800836
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with a history of or known presence of brain or spinal cord metastases
https://ClinicalTrials.gov/show/NCT03800836